Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer (Q37406114)

20 August 2017

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer (English)

1 reference

20 August 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Ulka N Vaishampayan

1

1 reference

20 August 2017

Shanthi Marur

2

1 reference

20 August 2017

Lance K Heilbrun

3

1 reference

20 August 2017

Michael L Cher

4

1 reference

20 August 2017

Brenda Dickow

5

1 reference

20 August 2017

Daryn W Smith

6

1 reference

20 August 2017

Samir A Al Hasan

7

1 reference

20 August 2017

James Eliason

8

1 reference

20 August 2017

language of work or name

English

0 references

publication date

17 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

182

1 reference

20 August 2017

1

1 reference

20 August 2017

317-323

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Pharmacology and clinical status of capecitabine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

The activity and expression of thymidine phosphorylase in human solid tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Optimal two-stage designs for phase II clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3869185

Demonstration of thymidine phosphorylase activity in human healthy, adenomatous and cancerous prostate

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19447430

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19447430

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JURO.2009.02.105

1 reference

release_rfxwmioa6jenxlceakr3msqave

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rfxwmioa6jenxlceakr3msqave

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

20 August 2017

1 reference